DOP2016000327A - (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1,2:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio - Google Patents
(2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1,2:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodioInfo
- Publication number
- DOP2016000327A DOP2016000327A DO2016000327A DO2016000327A DOP2016000327A DO P2016000327 A DOP2016000327 A DO P2016000327A DO 2016000327 A DO2016000327 A DO 2016000327A DO 2016000327 A DO2016000327 A DO 2016000327A DO P2016000327 A DOP2016000327 A DO P2016000327A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- oxazepin
- trifluorobenzyl
- pyrazino
- octahydro
- dioxo
- Prior art date
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- -1 2,4,6-TRIFLUOROBENZYL Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015245P | 2014-06-20 | 2014-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000327A true DOP2016000327A (es) | 2017-01-15 |
Family
ID=53674269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000327A DOP2016000327A (es) | 2014-06-20 | 2016-12-16 | (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1,2:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio |
Country Status (45)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (enExample) * | 2014-06-20 | 2018-06-23 | ||
| EP4233846B1 (en) * | 2015-06-30 | 2024-12-04 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| CN113546052A (zh) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | 治疗人免疫缺陷病毒的治疗组合物 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3506902A4 (en) * | 2016-08-31 | 2020-04-22 | VIIV Healthcare Company | COMBINATIONS AND USES AND TREATMENTS THEREOF |
| US20180085387A1 (en) * | 2016-09-27 | 2018-03-29 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| CN107445994A (zh) * | 2017-05-31 | 2017-12-08 | 北京阜康仁生物制药科技有限公司 | 替诺福韦艾拉酚胺半富马酸盐新晶型 |
| ES2916405T3 (es) | 2018-02-09 | 2022-06-30 | Sandoz Ag | Forma cristalina de bictegravir sódico |
| WO2019207602A1 (en) | 2018-04-26 | 2019-10-31 | Mylan Laboratories Limited | Polymorphic forms of bictegravir and its sodium salt |
| US11623933B2 (en) | 2018-06-28 | 2023-04-11 | Honour Lab Limited | Process for the preparation of sodium (2R,5S,13AR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1 ′,2′:4,5]pyrazino[2,1 -b] [1,3] oxazepin-8-olate and its polymorphic form |
| US20210393631A1 (en) * | 2018-09-19 | 2021-12-23 | Gilead Sciences, Inc. | Integrase inhibitors for the prevention of hiv |
| EP3653629A1 (en) | 2018-11-16 | 2020-05-20 | Sandoz AG | Acid addition salts of an integrase strand transfer inhibitor |
| WO2020161744A1 (en) | 2019-02-07 | 2020-08-13 | Cipla Limited | Novel polymorphs of integrase inhibitor |
| KR20240151256A (ko) | 2019-03-22 | 2024-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
| US12486286B2 (en) | 2019-06-18 | 2025-12-02 | Laurus Labs Limited | Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof |
| CN111978333B (zh) * | 2019-09-30 | 2021-06-18 | 常州制药厂有限公司 | Bictegravir钠盐的晶型A、制备方法及用途 |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| EP4153181B1 (en) | 2020-05-21 | 2026-07-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CN113698420A (zh) * | 2020-05-22 | 2021-11-26 | 上海迪赛诺生物医药有限公司 | 比克替拉韦钠的新晶型及其制备方法 |
| CN116390924B (zh) | 2020-09-30 | 2025-11-07 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| CN112409380A (zh) * | 2020-12-10 | 2021-02-26 | 上海迪赛诺生物医药有限公司 | 比克替拉韦钠的新晶型的制备方法及其应用 |
| CR20260070A (es) | 2021-01-19 | 2026-04-24 | Gilead Sciences Inc | COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315) |
| WO2022224120A1 (en) * | 2021-04-19 | 2022-10-27 | Honour Lab Limited | Polymorphic forms of bictegravir potassium |
| AU2022403012B2 (en) | 2021-12-03 | 2026-02-12 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2023248240A1 (en) | 2022-06-21 | 2023-12-28 | Mylan Laboratories Limited | Polymorphic forms of bictegravir sodium |
| US20240034724A1 (en) | 2022-07-01 | 2024-02-01 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| CN119768183A (zh) | 2022-08-26 | 2025-04-04 | 吉利德科学公司 | 用于广泛中和抗体的给药和安排方案 |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| EP4698174A1 (en) | 2023-04-19 | 2026-02-25 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| WO2024249573A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| CN122295099A (zh) | 2023-07-28 | 2026-06-26 | 吉利德科学公司 | 用于治疗和预防hiv的来那卡帕韦的每周方案 |
| AU2023462614A1 (en) | 2023-08-23 | 2026-03-19 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| IL327206A (en) | 2023-10-11 | 2026-05-01 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their uses |
| KR20260093341A (ko) | 2023-10-11 | 2026-06-19 | 길리애드 사이언시즈, 인코포레이티드 | 가교 트리시클릭 카르바모일피리돈 화합물 및 이의 용도 |
| AU2024360779A1 (en) | 2023-10-11 | 2026-04-16 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025260028A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788516A (fr) | 1971-09-10 | 1973-03-07 | Lonza Ag | Procede de fabrication d'esters alcoxyacetylacetiques |
| GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
| DE2658401A1 (de) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
| US4575694A (en) | 1984-03-05 | 1986-03-11 | Allied Corporation | Coaxial connector |
| DE3900736A1 (de) | 1989-01-12 | 1990-07-26 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches gemisch enthaltend einen mehrfunktionellen (alpha)-diazo-(beta)-ketoester, verfahren zu dessen herstellung und strahlungsempfindliches aufzeichnungsmaterial enthaltend dieses gemisch |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| DE4014649A1 (de) | 1990-05-08 | 1991-11-14 | Hoechst Ag | Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| WO1999025345A1 (en) | 1997-11-14 | 1999-05-27 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| DE69926148D1 (en) | 1998-11-09 | 2005-08-18 | Black James Foundation | Gastrin und cholecystokinin rezeptor ligande |
| GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
| BR9916583A (pt) | 1998-12-25 | 2001-09-25 | Shionogi & Co | Derivados heteroaromáticos tendo uma atividade inibitória contra integrase de hiv |
| EP1297834A4 (en) | 2000-06-14 | 2007-05-09 | Shionogi & Co | ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| NZ532018A (en) | 2001-10-03 | 2004-12-24 | Ucb S | Pyrrolidinone derivatives |
| DE122009000048I1 (de) | 2001-10-26 | 2010-04-08 | Angeletti P Ist Richerche Bio | N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase |
| WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| WO2004024078A2 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| US7176220B2 (en) | 2002-11-20 | 2007-02-13 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
| PT1583542E (pt) | 2003-01-14 | 2008-09-17 | Gilead Sciences Inc | Composições e métodos para terapia de combinação antiviral |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
| EP1725535A4 (en) | 2004-03-09 | 2009-11-25 | Merck & Co Inc | HIV integrase |
| WO2006028523A2 (en) | 2004-04-29 | 2006-03-16 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
| ES2529038T3 (es) | 2004-05-07 | 2015-02-16 | Merck Sharp & Dohme Corp. | Inhibidores de la integrasa de VIH |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| PT2258376T (pt) | 2004-07-27 | 2019-05-31 | Gilead Sciences Inc | Análogos fosfonatados de compostos inibidores do vih |
| JP4953297B2 (ja) | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| JP2006118669A (ja) | 2004-10-25 | 2006-05-11 | Sanoh Industrial Co Ltd | 樹脂チューブ |
| CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| WO2006088173A1 (ja) | 2005-02-21 | 2006-08-24 | Shionogi & Co., Ltd. | Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体 |
| CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
| DK3187225T3 (da) | 2005-04-28 | 2022-02-28 | Viiv Healthcare Co | Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet |
| US20070072831A1 (en) | 2005-05-16 | 2007-03-29 | Gilead Sciences, Inc. | Integrase inhibitor compounds |
| AU2006272521A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of HIV |
| TW200800988A (en) | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| US20070219243A1 (en) | 2005-12-30 | 2007-09-20 | Kearney Brian P | Method for improving the pharmacokinetics of HIV integrase inhibitors |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| EP1978960A4 (en) | 2006-02-01 | 2009-12-02 | Japan Tobacco Inc | USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION |
| CN101437801B (zh) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
| JP4669040B2 (ja) | 2006-03-06 | 2011-04-13 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物の製造方法 |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| CA2657034A1 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
| ES2536923T3 (es) | 2006-09-12 | 2015-05-29 | Gilead Sciences, Inc. | Proceso e intermedios para preparar inhibidores de la integrasa del VIH |
| CA2665538A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
| PT3150586T (pt) | 2007-02-23 | 2020-03-31 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
| SG182229A1 (en) | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| WO2009006203A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| EP2182801A4 (en) | 2007-07-31 | 2011-04-13 | Limerick Biopharma Inc | PYRONANALOGUE COMPOSITIONS AND CORRESPONDING METHODS |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| US8354429B2 (en) | 2007-11-16 | 2013-01-15 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0803019D0 (en) | 2008-02-19 | 2008-03-26 | Btg Int Ltd | Fluorinated compounds |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2010011813A1 (en) | 2008-07-23 | 2010-01-28 | Alkermes, Inc. | Complex of trospium and pharmaceutical compositions thereof |
| EP2660239B1 (en) | 2008-07-25 | 2016-11-23 | VIIV Healthcare Company | Chemical compounds as synthetic intermediates |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| ES2395705T3 (es) | 2008-07-25 | 2013-02-14 | Glaxosmithkline Llc | Compuestos químicos |
| WO2010011812A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| EP3617194B1 (en) | 2008-12-11 | 2023-11-08 | VIIV Healthcare Company | Processes and intermediates for carbamoylpyridone hiv integrase inhibitors |
| SG171308A1 (en) | 2008-12-11 | 2011-07-28 | Shionogi & Co | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| JP5737691B2 (ja) | 2009-06-15 | 2015-06-17 | 塩野義製薬株式会社 | 置換された多環性カルバモイルピリドン誘導体 |
| US8637674B2 (en) | 2009-09-02 | 2014-01-28 | Ewha University-Industry Collaboration Foundation | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same |
| EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
| CN102858771A (zh) | 2010-02-26 | 2013-01-02 | 日本烟草产业株式会社 | 1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的用途 |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| CN103140474A (zh) | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | 治疗aids的萘-2-基乙酸衍生物 |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| SMT202100268T1 (it) | 2010-08-05 | 2021-07-12 | Shionogi & Co | Metodo per produrre composti aventi attività di inibizione di integrasi di hiv. |
| LT2620436T (lt) | 2010-09-24 | 2018-08-10 | Shionogi & Co., Ltd. | Pakeistojo policiklinio karbamoilpiridono darinio provaistas |
| WO2012106534A2 (en) | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| MX2013012266A (es) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
| WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| US9121496B2 (en) | 2011-06-29 | 2015-09-01 | Arvinmeritor Technology, Llc | Drive axle system and a method of control |
| CA2840095A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PL2742051T3 (pl) | 2011-09-14 | 2017-06-30 | Mapi Pharma Limited | Amorficzna postać soli sodowej dolutegrawiru |
| AU2012321762A1 (en) | 2011-10-12 | 2014-04-17 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| US9643974B2 (en) | 2011-12-12 | 2017-05-09 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| JP6144698B2 (ja) | 2011-12-20 | 2017-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｉｖ複製の阻害剤としての縮合三環式化合物 |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
| US20150218164A1 (en) | 2012-07-25 | 2015-08-06 | Merck Sharp & Dohme Corp. | Substituted naphthyridinedione derivatives as hiv integrase inhibitors |
| EP2880017B1 (en) | 2012-08-03 | 2016-10-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| AU2013341200A1 (en) | 2012-11-08 | 2015-07-02 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| CN104902905A (zh) | 2012-12-14 | 2015-09-09 | 葛兰素史克有限责任公司 | 药物组合物 |
| EP2931730B1 (en) | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| WO2014100077A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
| US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| HK1214817A1 (en) | 2012-12-27 | 2016-08-05 | Japan Tobacco Inc. | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor |
| US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| CA2924829C (en) | 2013-09-27 | 2019-10-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| US9856271B2 (en) | 2014-01-21 | 2018-01-02 | Laurus Labs Limited | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
| WO2015138933A1 (en) | 2014-03-13 | 2015-09-17 | Assia Chemical Industries Ltd. | Solid state forms of dolutegravir sodium |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (enExample) * | 2014-06-20 | 2018-06-23 | ||
| CN113546052A (zh) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | 治疗人免疫缺陷病毒的治疗组合物 |
-
2012
- 2012-06-06 NO NO12796397A patent/NO2717902T3/no unknown
-
2015
- 2015-06-17 TW TW104119604A patent/TWI673274B/zh active
- 2015-06-17 UY UY0001036177A patent/UY36177A/es not_active Application Discontinuation
- 2015-06-17 TW TW108122266A patent/TWI731354B/zh active
- 2015-06-18 AR ARP150101953A patent/AR100903A1/es active IP Right Grant
- 2015-06-18 MA MA40239A patent/MA40239B1/fr unknown
- 2015-06-19 ES ES17204116T patent/ES3010114T3/es active Active
- 2015-06-19 LT LTEP15739063.4T patent/LT3157932T/lt unknown
- 2015-06-19 BR BR122021025861-9A patent/BR122021025861B1/pt active IP Right Grant
- 2015-06-19 CA CA2950307A patent/CA2950307C/en active Active
- 2015-06-19 DK DK15739063.4T patent/DK3157932T3/en active
- 2015-06-19 CR CR20160589A patent/CR20160589A/es unknown
- 2015-06-19 US US14/744,915 patent/US9708342B2/en active Active
- 2015-06-19 CN CN201910478532.9A patent/CN110563747A/zh active Pending
- 2015-06-19 PL PL17204116.2T patent/PL3321270T3/pl unknown
- 2015-06-19 JP JP2016574180A patent/JP6334007B2/ja active Active
- 2015-06-19 PL PL15739063T patent/PL3157932T3/pl unknown
- 2015-06-19 US US15/320,656 patent/US20170197985A1/en not_active Abandoned
- 2015-06-19 MX MX2019013380A patent/MX383272B/es unknown
- 2015-06-19 SI SI201530163T patent/SI3157932T1/en unknown
- 2015-06-19 EA EA201692414A patent/EA030967B1/ru unknown
- 2015-06-19 AP AP2016009591A patent/AP2016009591A0/en unknown
- 2015-06-19 EP EP24215783.2A patent/EP4523758A3/en active Pending
- 2015-06-19 MD MDA20170006A patent/MD4584C1/ro active IP Right Grant
- 2015-06-19 WO PCT/US2015/036757 patent/WO2015196116A1/en not_active Ceased
- 2015-06-19 MY MYPI2016704591A patent/MY186696A/en unknown
- 2015-06-19 KR KR1020177001377A patent/KR101899803B1/ko active Active
- 2015-06-19 SG SG11201610211QA patent/SG11201610211QA/en unknown
- 2015-06-19 NZ NZ727155A patent/NZ727155A/en unknown
- 2015-06-19 MD MDA20180037A patent/MD20180037A2/ro not_active Application Discontinuation
- 2015-06-19 AU AU2015276860A patent/AU2015276860B2/en active Active
- 2015-06-19 PE PE2016002742A patent/PE20170150A1/es unknown
- 2015-06-19 HR HRP20180455TT patent/HRP20180455T1/hr unknown
- 2015-06-19 SM SM20180053T patent/SMT201800053T1/it unknown
- 2015-06-19 MX MX2016016059A patent/MX369555B/es active IP Right Grant
- 2015-06-19 BR BR112016029605-2A patent/BR112016029605B1/pt active IP Right Grant
- 2015-06-19 MA MA044221A patent/MA44221A/fr unknown
- 2015-06-19 PT PT157390634T patent/PT3157932T/pt unknown
- 2015-06-19 TR TR2018/02179T patent/TR201802179T4/tr unknown
- 2015-06-19 ME MEP-2018-73A patent/ME03037B/me unknown
- 2015-06-19 CU CU2016000187A patent/CU24478B1/es unknown
- 2015-06-19 UA UAA201613232A patent/UA118480C2/uk unknown
- 2015-06-19 HU HUE15739063A patent/HUE036928T2/hu unknown
- 2015-06-19 EA EA201891464A patent/EA201891464A1/ru unknown
- 2015-06-19 EP EP17204116.2A patent/EP3321270B1/en active Active
- 2015-06-19 ES ES15739063.4T patent/ES2660862T3/es active Active
- 2015-06-19 RS RS20180286A patent/RS56950B1/sr unknown
- 2015-06-19 CN CN201580033152.4A patent/CN106459085B/zh active Active
- 2015-06-19 EP EP15739063.4A patent/EP3157932B1/en not_active Revoked
-
2016
- 2016-11-23 IL IL249161A patent/IL249161B/en active IP Right Grant
- 2016-12-14 PH PH12016502499A patent/PH12016502499B1/en unknown
- 2016-12-16 SV SV2016005339A patent/SV2016005339A/es unknown
- 2016-12-16 CL CL2016003249A patent/CL2016003249A1/es unknown
- 2016-12-16 DO DO2016000327A patent/DOP2016000327A/es unknown
- 2016-12-19 ZA ZA2016/08744A patent/ZA201608744B/en unknown
- 2016-12-21 EC ECIEPI201695566A patent/ECSP16095566A/es unknown
-
2017
- 2017-06-15 US US15/624,166 patent/US10385067B2/en active Active
-
2018
- 2018-03-13 CY CY20181100305T patent/CY1120025T1/el unknown
- 2018-04-25 JP JP2018083840A patent/JP2018162246A/ja active Pending
- 2018-05-08 AU AU2018203175A patent/AU2018203175B2/en active Active
-
2020
- 2020-01-24 JP JP2020010135A patent/JP2020097593A/ja active Pending
-
2022
- 2022-03-15 JP JP2022039909A patent/JP2022095640A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16095566A (es) | (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1,2:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio | |
| PL3564244T3 (pl) | Krystaliczne postacie (2r,5s,13ar)-8-hydroksy-7,9-diokso-n-(2,4,6-trifluorobenzylo)-2,3,4,5,7,9,13,13a-oktahydro-2,5-metanopirydo[1’,2’:4,5]pirazyno[2,1-b][1,3]oksazepino-10-karboksyamidu | |
| HK1235402A1 (en) | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide | |
| TN2013000364A1 (fr) | تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة |